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SObjective: Our objective was to evaluate whether platinum concentrations in chest wall tissue and in serum are
optimized by intracavitary application of cisplatin loaded to a fibrin carrier compared with cisplatin solution in
a randomized setting of a pig model.
Methods: After left-sided pneumonectomy including parietal pleurectomy, pigs were randomly assigned to re-
ceive either 90 mg/m2 cisplatin intracavitary solution (n ¼ 6) or to receive 5 mg cisplatin-fibrin (n ¼ 5) applied
on a predefined area of the chest wall. Platinum concentration in serum as well as in chest wall tissue was de-
termined at several early time points until day 5 after treatment. Platinum levels were measured by inductively
coupled plasma sector field mass spectrometric detection with a matrix-matched calibration procedure.
Results: The dose- and surface-corrected (geometric) mean concentration of cisplatin in chest wall tissue 2
hours but also at day 5 after the application was doubled in animals treated with cisplatin-fibrin compared
with the animals treated with cisplatin-solution. In serum, the dose- and surface-corrected exposure toward cis-
platin (area under the curve0-5d) was significantly lower with cisplatin-fibrin than with cisplatin-solution
(P<.0005). This is also reflected by significantly reduced serum creatinine and urea values in the cisplatin-
fibrin group (P<.0001). Animals treated with cisplatin-fibrin additionally had a significantly better postoper-
ative course as assessed by a well-being score (P<.001).
Conclusions:After cisplatin-fibrin treatment, cisplatin tissue concentration was increased whereas systemic cis-
platin concentrations were significantly reduced in comparison with cisplatin-solution treatment. This finding
offers a clear advantage inasmuch as rate and severity of systemic adverse events can be reduced while local
cytotoxic concentrations are at least maintained. (J Thorac Cardiovasc Surg 2011;141:65-71)Although overall survival data for patients with malignant
pleural mesothelioma were positively influenced by multi-
modal treatment concepts over the past decade,1,2
malignant pleural mesothelioma remains a malignancy
with a high rate of local recurrence in a median time
around 16 months only. Therefore, new therapeutic
strategies to improve local tumor control are required.
One particular approach is intracavitary chemotherapy.
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The Journal of Thoracic and Caccessibility to the large surface of the pleura and the
possibility to reduce systemic side effects by increasing
the desired local effect. The feasibility of intrapleural
cisplatin-based chemotherapy (CDDP) was proven by sev-
eral groups in clinical phase I or II studies.3-10 The results
indicate the distinct pharmacokinetic advantage of this
treatment with high intrapleural chemotherapeutic drug
levels.11 However, treatment-related morbidity of up to
49% and mortality of up to 11% are reported4,10 whereas
median overall survivals (11–16 months) do not exceed
the those reported for induction chemotherapy plus
extrapleural pneumonectomy (23 months).1,2 One of the
major drawbacks of this application form is the rapid
absorption of the drug applied, leading to high systemic
levels with corresponding side effects such as renal
dysfunction. Therefore, further refinement of the
intrapleural chemotherapy regimen is required to increase
the efficacy of local cisplatin application with maintained
dosages and decrease the treatment-related toxicity.
In previous small animal studies,we12 demonstratedhigher
local concentrations of intracavitary cisplatin (CDDP) if
combined with fibrin, whereas systemic concentrations are
reduced in comparison to CDDP-solution. Furthermore, we
have proven important reduction of tumor recurrence by
intracavitary application of cisplatin in an orthotopicardiovascular Surgery c Volume 141, Number 1 65
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
CDDP ¼ cisplatin
CI ¼ confidence interval
CV ¼ coefficient of variation
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Smesothelioma recurrence model. Tumor recurrence was sig-
nificantly decreased if CDDP-fibrin or CDDP-solution was
applied to the chest cavity after pneumonectomy.13
The aim of the present study was to compare platinum
local tissue and systemic serum concentrations after
pneumonectomy followed by intracavitary application
of CDDP-fibrin in comparison with CDDP-solution in
a preclinical pig model.METHODS
Animal care was provided in accordance with the ‘‘Guide for the Care
and Use of Laboratory Animals’’ (National Institutes of Health Publication
No. 85-23, revised 1996; Bethesda, Md) and in compliance with the Euro-
pean Convention on Animal Care. The study protocol was approved by the
local animal committee.
Study Design
Eleven domestic pigs were randomly divided into 2 groups: The cis-
platin (CDDP)-solution group (n ¼ 6) received 90 mg of cisplatin per
square meter of body surface area diluted in 500 mL of sodium chloride
0.9% into the chest cavity according to the dosages described in the liter-
ature.5 The CDDP-fibrin group (n¼ 5) received 5mg of cisplatin combined
to the fibrin sealant Vivostat on a predefined area of 103 10 cm of the chest
wall. Vivostat (Vivolution) is a commercially available autologous surgical
fibrin sealant and CDDP fibrin was prepared as described previously.12 For
comparison of both groups, a dose- and application surface–dose correc-
tion of the CDDP concentrations measured was performed (see Pharmaco-
logic Analysis).
Surgery
Before intracavitary application of CDDP, a left-sided pneumonectomy
and subtotal pleurectomy—imitating the procedure of extrapleural pneu-
monectomy in humans—was performed via lateral thoracotomy in the
fifth intercostal space. According to the randomization, CDDP was ad-
ministered as a solution or sprayed in combination with fibrin throughout
a trocar in the left hemithorax. Cisplatin-fibrin was applied on the inside
of the dorsolateral chest cavity. The animals were kept under narcosis for
4 hours. At time points 2 and 4 hours after CDDP administration, video-
assisted thoracic surgery biopsy specimens (2 superficial and 2 deep) from
the chest wall were obtained after removal of the CDDP-fibrin film. A
chest tube was placed temporarily and was removed before extubation.
The animals were under veterinarian supervision during the whole obser-
vation period of 5 days, and a well-being score measuring body temper-
ature, breathing and heart rate, feeding and drinking behavior, mobility
of the animals, posture of the animals, pain signs, and the use of analge-
sics (maximum of 5 points per criterion) was assessed several times a day.
On days 2 and 5 after intracavitary application of cisplatin, we obtained
pleural biopsy specimens by video-assisted access from the left chest
wall in deep sedation. On the fifth day the animals were humanely killed
in deep general anesthesia.66 The Journal of Thoracic and Cardiovascular SurgeSamples
Tissue samples (superficial and deep) of the chest wall were obtained
2 and 4 hours and 2 and 5 days after intracavitary application of cisplatin
after removal of the CDDP-fibrin film. The use of special thoracoscopic
forceps guaranteed standardized biopsy specimens of 2 different depths:
superficial (0.5 cm containing tissue of the endothoracic fascia and super-
ficial layer of intercostal muscle) and deep (1.5 cm containing tissue of
the deeper layers of intercostal muscle). In detail, in cisplatin-solution an-
imals, we took biopsy tissue both from the lateral and from the dorsal chest,
mostly from the region of the sixth to eighth intercostal space to reach parts
of the chest wall that were covered with the solution. In cisplatin-fibrin an-
imals, we first removed the CDDP-fibrin sealant film over the region se-
lected for biopsy and subsequently performed the biopsy procedures in
the sameway that we did in the other group. The biopsy tissues were frozen
at20C for later duplicate platinum level determination.
Blood samples were taken before treatment (baseline), at 1, 2, 4, 8, 12,
24 hours, and 2 and 5 days after intracavitary cisplatin instillation. The
blood was coagulated in serum tubes and was centrifuged. The supernatant
was frozen at20C for later duplicate platinum level determination. Lab-
oratory findings included determination of hemoglobin, hematocrit, white
blood cells, platelets, urea, and creatinine. Liver parameters (lactate dehy-
drogenase, aspartate aminotransferase, glutamate–pyruvate transaminase,
and alkaline phosphatase) were determined before the operation, 8 and
24 hours after cisplatin instillation, and on days 2 and 5.
Urine samples were collected before treatment and from 2- and 4-hour
pools via urinary catheter. The samples were frozen at 20C for later
duplicate platinum level determination.
The level of total platinum in all samples was measured by inductively
coupled plasma sector field mass spectrometric detection with a matrix-
matched calibration procedure at the Department of Inorganic Chemistry,
ETH, as described previously.14,15
Pharmacologic Analysis
To guarantee comparability of the results between both treatment groups,
we calculated a dose and surface correction of the concentrations measured
in the serum and chest wall tissue as follows: the measured CDDP-
concentration value was divided by a variable x. For the CDDP-fibrin–
receiving group, x equaled the applied amount of CDDP (5 mg) divided
by the CDDP-applied area of the chest wall (10 $ 10 cm) ¼> x ¼ 0.05.
For the CDDP-solution group, x equaled the applied amount of CDDP
(which was calculated for each pig according to body surface area) divided
by the total pleural surface area, which was measured with the help of volu-
metry on a computed tomographic scan of a 50-kg pig as 900 cm2 because
there were no data available in the literature about the pleural surface of
pigs. Inasmuch as the anatomic geometry of the swine chest cavity is similar
to a pyramid, the arithmetic formula for pyramid was used to approximate
the pleural surface, but using only 3 planes. The length of the base corre-
sponds to the distance from the spine to the lateral side of the pleura, and
the height corresponds to the distance from apex to base.
All CDDP concentrations at the different time points were compared be-
tween both groups, the maximum concentration determined as well as the
area under the concentration–time curve from 0 to 120 hours after surgery.
For analysis of the excreted CDDP amount in the urine, the measured
CDDP concentrations in urine samples were multiplied by the measured
volume of urine excreted in the different time periods (0–2 hours, 2–4
hours).
Statistical Analysis
Sample size was calculated with the help of the program ‘‘nQueryAdvi-
sor’’ (Elasthoff, 1995). A sample size of 5 animals in each group would
have 80% power to detect a difference in means of 2.1 standard deviations
using a 2-group t test with a .05 2-sided significance level. Statistical anal-
ysis was carried out using the software package SPSS (version 12.0; SPSS
Inc, Chicago, Ill), and WinNonlin 5.2 (Pharsight, Mountain View, Calif)ry c January 2011
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standard deviation or, to account for ln-normal distribution of
concentration-dependent data, as geometric mean and geometric coeffi-
cient of variation (CV). This was calculated as CV ¼ 100 $ O(es2 1),
where e is Euler’s number and s2 is the mean square error of analysis of
variance (ANOVA) testing. For statistical analysis and pharmacokinetic
comparison between groups, concentration-dependent data were ln-
transformed. A repeated-measures ANOVAwas carried out to test for a dif-
ference between the groups over the whole time period of measurements.FIGURE 1. Creatinine (mmol/L) measured in the plasma at several time
points in both groups: CDDP-fibrin and CDDP-solution. Data are log trans-
formed and given as mean and standard deviation.
TABLE 1. Geometric means and coefficients of variation (CV) of
maximum measured CDDP concentration (Cmax), and area under
the curve (AUC), measured in the superficial tissue of the chest wallRESULTS
Animal Well-Being and Analysis of the Blood
All animals survived the experiment until the autopsy at
day 5 except for 1 animal of the cisplatin-solution group,
which died at the end of surgery owing to proven bacterial
sepsis. This animal was replaced, but the values measured
during the first 4 hours of the deceased animal were not ex-
cluded from analysis. The animals of both treatment groups
were comparable. No significant differences in the preoper-
ative weight were observed: cisplatin-fibrin group (n ¼ 5),
with a mean weight of 50.7 kg (standard deviation, 3.44),
and control cisplatin-solution group (n ¼ 6), with a mean
weight of 52.3 (standard deviation, 3.9); P>0.05. The ani-
mals’ well-being during the experiments was evaluated on
a daily basis in a repeated manner by means of a score sys-
tem that showed a significant difference between both
groups from the day of surgery up to the day of planned
death. The animals of the cisplatin-fibrin group had a signif-
icantly better postoperative course than did the control group
(repeated-measures ANOVA, P<.001 for interaction).
The analysis of leukocytes, hematocrit, thrombocytes, and
liver enzymes (lactate dehydrogenase, aspartate aminotrans-
ferase, alkaline phosphatase, and gamma-glutamyl transfer-
ase), revealed no significant differences between the groups
(P>.05). The number of leukocytes increased after treatment
with a maximum at 8 hours for the CDDP-fibrin group and at
12 hours for the CDDP-solution group. Thrombocyte counts
remained almost unchanged up to day 5 after treatment, at
which point they showed a steep increase in both groups.
The hematocrit value was increased in the time period of
8 hours up to day 1 after treatment in both groups. Significant
difference between both groups was observed concerning
retention values, such as creatinine and urea (Figure 1):
creatinine values for the CDDP-fibrin group were signifi-
cantly lower from the time point 8 hours until 5 days after
treatment (repeated-measures ANOVA, P<.0001 for inter-
action). The same significant difference was observed for
urea values, with an important increase from 12 hours on
until day 5 in the CDDP-solution–treated group (repeated-
measures ANOVA, P<.0001 for interaction).of both groups CDDP-fibrin and CDDP-solution (P>.05)
Geometric
mean (CV%)
Cmax 2 hours
(mg/kg)
AUC
(mg/kg $ h)
CDDP-fibrin 504 (88) 27,962 (54)
CDDP-solution 249 (261) 9,784 (691)CDDP Concentration in the Tissue of the Chest Wall
The dose- and application surface–corrected geometric
mean concentration of CDDP in superficial tissue of the
chest wall reached maximum values 2 hours after the appli-The Journal of Thoracic and Ccation. In animals treated with CDDP-fibrin, a mean maxi-
mum of 504 mg/kg was observed (geometric CV, 88%),
whereas animals receiving CDDP-solution had a mean
maximum tissue concentration of 249 mg/kg (CV 261%).
Although the point estimate of the ratio of the values in
CDDP-fibrin–treated animals over the values in CDDP-
solution–treated animals showed roughly 2-fold higher con-
centrations obtained with CDDP-fibrin (point estimate
202%), the 90% confidence intervals (90% CI) included
unity (55%–751%), and therefore differences were not sta-
tistically significant (P>.05). Five days after the applica-
tion, mean concentrations in superficial tissues of the
chest wall were 73 mg/kg (CV 216%) and 22 mg/kg (CV
427%) in CDDP-fibrin– and CDDP-solution–treated
animals, respectively (point estimate 332%, 90% CI
55%–2015%). CDDP in superficial chest wall tissue
tended to be higher and longer, respectively, in the group
of animals treated with CDDP-fibrin (P>.05) (Table 1).ardiovascular Surgery c Volume 141, Number 1 67
FIGURE 2. Geometric mean CDDP concentrations (mg/L) in serummea-
sured at several time points in both groups of animals treated with CDDP-
fibrin and CDDP-solution, respectively. Data are given as geometric mean
and geometric standard deviations. Please note the logarithmic scale of the
y-axis.
General Thoracic Surgery Opitz et al
G
T
SThe differences in dose- and application surface–
corrected area under the curve of CDDP in deep tissue of
the chest wall between the groups were not so important
as observed in the superficial tissues (P> .05) (Table 2).
This was also reflected in comparably high maximum
CDDP concentrations: 72 mg/kg (1269%) for CDDP-
fibrin after 2 hours and 73 mg/kg (1303%) for CDDP-
solution after 4 hours. Nevertheless, the point estimate for
the ratio of CDDP concentrations in deep tissues 5 days af-
ter the application of 134% (90% CI 31%–574%) showed
that CDDP concentrations in deep tissue tended to be higher
in the cisplatin-fibrin group.
CDDP Serum Concentrations
In serum, the dose- and application surface–corrected ex-
posure toward CDDP (area under the concentration-time
curve from 0–120 hours after surgery) was clearly and
significantly lower in animals treated with CDDP-fibrin in
comparison with animals treated with CDDP-solution:
69 mg/L $ h (CV 28%) versus 756 mg/ L $ h (CV
110%), point estimate of the ratio of means in the fibrin-
treated group over the means in the solution-treated group:
9% (90% CI, 4%–20%) (P<.0005) (Figure 2). The same
was true for the maximum values of CDDP in serum, with
a point estimate of 15% (90% CI, 10%–25%), meaning
a reduction by 85% of maximum CDDP concentrations
in the serum for the animals treated with cisplatin-fibrin.
CDDP Amount Excreted in the Urine
The amount of CDDP excreted in urine during 0 to 2
hours and 2 to 4 hours after CDDP application was signifi-
cantly lower in the CDDP-fibrin–treated animals than in the
cisplatin-solution–treated pigs (P<.0001) (Figure 3).
DISCUSSION
In this preclinical animal study, CDDP chest wall tissue
concentration after CDDP-fibrin treatment was increased
whereas systemic CDDP concentration was significantly
reduced. The reduced systemic drug concentrations are re-
flected in significantly lower serum creatinine and urea
levels as well as better well-being scores in animals treated
with CDDP-fibrin. Together with the results of our previous
small animal studies in our mesothelioma recurrence
model, where intracavitary cisplatin-fibrin and cisplatin-
solution are equally efficient in reducing tumor recurrence,TABLE 2. Geometric means and coefficients of variation (CV) of
maximum CDDP concentration (Cmax) and the area under the
curve (AUC) in the deep tissue of the chest wall of both groups
(CDDP-fibrin and CDDP-solution, P>.05)
Geometric
mean (CV%)
Cmax 2 hours
(mg/kg)
AUC
(mg/kg $ h)
CDDP-fibrin 72 (1269) 4408 (101)
CDDP-solution 52 (540) 3875 (254)
68 The Journal of Thoracic and Cardiovascular Surgethe finding of the present study demonstrates a clear advan-
tage of CDDP-fibrin inasmuch as rate and severity of sys-
temic adverse events can be reduced while local cytotoxic
concentrations are at least maintained.FIGURE 3. Amount of CDDP excreted in urine measured during 2 time
periods from 0 to 2 and from 2 to 4 hours after CDDP application. Data
are given as geometric means and geometric standard deviations. Please
note the logarithmic scale on the y-axis.
ry c January 2011
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CDDP-solution, as used by many other groups,3-5,7-10
might be a therapy option to decrease treatment-relatedmor-
bidity of the latter.Mortality rates up to 11% and a risk of up
to 57% for renal toxicity and 13% for deep venous throm-
bosis and pulmonary embolus3,4,10 can be explained by
rapid absorption of cisplatin from the pleural cavity with
high systemic drug levels when applied as a solution.
Several renal protective measures have been undertaken
for this problem, for example, postoperative hydration,
which cannot be performed in the setting of extrapleural
pneumonectomy to avoid excessive contralateral fluid
retention. Other measures investigated are the application
of amifostine,3 with still inadequate renal protection; also,
after the combination of amifostinewith sodium thiosulfate,
the overall risk of renal dysfunction is 14%.10 The use of
cisplatin bound to a fibrin carrier might prevent the problem
of renal toxicity by preventing rapid absorption. The fibrin
sealant acts as a depot for cisplatin, fromwhich it is released
during a longer time period than after application of a cis-
platin solution into the pleural cavity, which is rapidly ab-
sorbed. If we assume that the transport to deeper tissues
(and then to the blood) is mainly a first-order diffusion pro-
cess and not saturated by the concentrations achieved, but
that the application is maintained for a longer time with
CDDP-fibrin, a higher local exposure (area under the curve)
after the application of the fibrin-cisplatin mixturewould re-
sult from the slower absorption of CDDP from the fibrin
sealant. Additionally, local concentrations are higher, be-
cause cisplatin readily binds to proteins and is presumably
thereby better retained at the application site if concentra-
tions are maintained for a longer time. Inasmuch as we cor-
rected for both dose and application surface, the depot effect
and the more effective tissue protein binding when cisplatin
exposure is maintained for a longer time period could ex-
plain higher local concentrations and lower systemic expo-
sure, since the liberation of cisplatin from protein binding is
a very slow process. This is underlined by the fact that we
reach with cisplatin-fibrin at least the same local tissue con-
centrations as with cisplatin-solution, although the applied
amount of cisplatin per square centimeter is lower. One
might think about even further increasing the cisplatin-
application dosage with the help of cisplatin-fibrin.
Cisplatin shows cytotoxic growth arrest in vitro on human
mesothelioma cell lines in the micromolar range. The con-
centrations obtained in the superficial and deep chest wall
tissue in both groups exceed the concentration necessary
to produce necrosis (1 mmol/L ¼ 300 mg/L) by more than
factor 1000. The cytotoxic potential of CDDP-fibrin was
also tested in vitro after cisplatin elution in solution (data
not shown) on a human mesothelioma cell line beforehand,
and we observed a dose-dependent cell killing. Thus, even-
tually this compound can be used to apply even higher
dosages than the one tested in clinical studies ranging upThe Journal of Thoracic and Cto 225 mg/m2 as maximum tolerated dose.4 With these con-
centrations, Sugarbaker and associates have proven distinct
survival advantage of 26 months for those patients receiving
high-dose cisplatin lavage.4 Another difference of our proto-
col in contrast to other groups is that we decided not to add
hyperthermia to our treatment protocol. Our reason was that
hyperthermia influences the process of platelet activation,16
fibrin formation,17 and fibrinolysis18—complications for
which patients with malignant pleural mesothelioma are al-
ready at high risk owing to the malignancy itself. Although
The Brigham and Women’s Hospital group looks back now
on a great experience with hyperthermic intraoperative che-
motherapy and refined the protocol more and more over the
past years, the procedure itself remains complex, with a 60-
minute lavage, and is not easy for other centers to copy.
Therefore, our application system with a spray-pen that
covers the whole chest cavity or distinct areas with cisplatin
film seems to facilitate the practical aspect.
A critical point of the study is the variability of the data
reflected in large coefficients of variation. This variation,
especially in the biopsy tissues, can be explained by the
modus of tissue concentration assessment. Although we al-
ways used the same forceps and followed a standardized
scheme of biopsy, there might be a certain interexamination
variability. The variability of the data is probably also due to
the limited sample size of only 5 animals per group. Never-
theless, there is a clear trend recognizable of not only signif-
icantly decreased serum but also increased CDDP tissue
concentration after CDDP-fibrin treatment. Another point
for discussion is that the fibrin sealant applies the chemo-
therapy to a specific area covered by the sealant, whereas
the solution reaches the entire pleural cavity. As already
mentioned, the dose- and application-surface normalization
was intended to make the 2 treatment strategies comparable
in terms of local tissue concentrations and systemic expo-
sure irrespective of the dose and the absorption surface.
If one considers our results of previous small animal stud-
ies and the clinical studies of other groups, the use of intra-
pleural chemotherapy is an attractive approach to improve
local tumor control because 50% reduction of ipsilateral re-
currence was proven (Tilleman and associates10: 34%) in
comparison with historical controls (Baldini and associ-
ates19: 67%). The CDDP-fibrin approach seems to be an at-
tractive alternative to decrease renal toxicity and may be
a vehicle to reach increased local toxicity. On the one
hand, CDDP-fibrin can be used clinically as an alternative
treatment option combined with less radical procedures
such as pleurectomy/decortication for patients who are un-
likely to benefit from an aggressive multimodal regimen
(eg, patients with insufficient cardiopulmonary reserve, ad-
vanced age, or disease pattern). Alternatively, CDDP-fibrin
can be used as an additional treatment option if, during rad-
ical surgery, zones potentially at risk for recurrence are
identified and ‘‘prophylactically’’ treated with topicalardiovascular Surgery c Volume 141, Number 1 69
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Scisplatin-fibrin, which has to be further evaluated. In a next
step, we will further evaluate the application of cisplatin-
fibrin on the whole surface of the chest cavity before start-
ing a clinical phase I study.
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Dr W. Roy Smythe (Temple, Tex). I appreciate the opportunity
to comment on this paper and I also thank the authors for sending
the manuscript ahead of time. Walt Whitman said the art of art, the
glory of expression, and the sunshine of the light of letters is sim-
plicity. The use of intrapleural chemotherapy for an intrapleural
malignancy suggests Whitman’s simplicity; however, this tech-
nique, which was originally experimentally pioneered by Valerie
Rusch and colleagues at Memorial Sloan–Kettering and David
Sugarbaker and his colleagues at Brigham, followed by more
than a decade of clinical use, pioneering clinical use by the Brig-
ham group, has been less than anticipated. In all likelihood, most
of the issues with this approach have related to the lack of persis-
tence of the drug at the site and then the associated toxicities,
which your group has mentioned. I think this study, on the other
hand, is very simple and elegant and begins to address some
of these issues. I have the following questions: First, is there any
evidence that the fibrin carrier interacts with the drug, either
augmenting or attenuating the effect of the drug? I noticed that
the snake-derived venom, batroxobin, is used in this formulation.
Batroxobin, for example, is a serine protease, which has been
shown itself in many animal models of malignancy to have an
antitumor effect.
Dr Opitz. We could not address this in the pig model because
this is not a tumor model. However, in our previous small animal
studies, we also analyzed a group treated with fibrin alone and we
observed no antitumor efficacy with fibrin alone.
Dr Smythe. Very good. The second question is, if the major
mechanism of action here is the film holding the drug in place
for a period of time, that would suggest that other drugs or even
biological agents might be applicable to this model. Have you tried
those in the past in any of your models?
DrOpitz.We have tried chemokines that were topically applied
and we have tried CpG-ODNs, but the efficacy was not higher with
these drugs if combined to fibrin in comparison to cisplatin, as it is
already very active. However, there are a lot of options to test this
in the future. Any drug can be combined with fibrin.
Dr Smythe. The last question is, one of the other issues with in-
trapleural chemotherapy, one of the reasons some groups have
used heated chemotherapy rather than just simple installation, is
depth of penetration of the drug. A group that I previously worked
with showed in 2005 that if you use a liposomal formulation of cis-
platin, you can get better depth of penetration in tumor. Have you
considered perhaps using this fibrin carrier in combination with
a lipid carrier to maybe titrate depth of penetration?
Dr Opitz. We discussed this issue during the setup of our pro-
tocol. However, in the literature, there is really a high rate ofry c January 2011
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Spulmonary embolism and deep venous thrombosis in the clinical
phase I and phase II studies, and it has been demonstrated that
hyperthermia leads to fibrin formation or disorganization of the
whole coagulation cascade. We decided for our protocol not to
use hyperthermia.
Dr Steven J. Mentzer (Boston, Mass). A poorly recognized
biological characteristic of cisplatin is that it can generate anThe Journal of Thoracic and C
Gimmunologic response by directly modifying class I peptides. It
is possible that some of the clinical response you observe may
be immunologically mediated? The potential immunologic activ-
ity of cisplatin raises concerns about the biological availability
of cisplatin after fibrin conjugation. Do you have any data that
cisplatin is biologically active?
Dr Opitz. No, we do not have any data.ardiovascular Surgery c Volume 141, Number 1 71
